BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 32220886)

  • 1. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
    Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
    Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
    J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma.
    D'Alfonso TM; Pareja F; Da Cruz Paula A; Vahdatinia M; Gazzo A; Ferrando L; da Silva EM; Cheng E; Sclafani L; Chandarlapaty S; Zhang H; Hoda SA; Wen HY; Brogi E; Weigelt B; Reis-Filho JS
    J Pathol Clin Res; 2021 Mar; 7(2):113-120. PubMed ID: 33263939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
    Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
    Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular Carcinomas
    Lee JY; Schizas M; Geyer FC; Selenica P; Piscuoglio S; Sakr RA; Ng CKY; Carniello JVS; Towers R; Giri DD; de Andrade VP; Papanastasiou AD; Viale A; Harris RS; Solit DB; Weigelt B; Reis-Filho JS; King TA
    Clin Cancer Res; 2019 Jan; 25(2):674-686. PubMed ID: 30185420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
    Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
    Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
    Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
    Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
    Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
    Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumor Heterogeneity of Synchronous
    Kim H; Gim JA; Kim CY; Kim A
    Anticancer Res; 2021 Aug; 41(8):3779-3787. PubMed ID: 34281837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
    Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
    Xu S; Wei B; Zhang H; Qing M; Bu H
    Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
    Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.